Harmony Biosciences Holdings, Inc. reported a net product revenue of $215.4 million for the first quarter of 2026, marking a 16.6% increase from $184.7 million in the same period of 2025. The growth was attributed to a 12.1% rise in the number of units shipped and a 7% price increase, which was partially offset by higher rebates. However, the company's net income decreased to $32.5 million, down from $45.6 million year-over-year, resulting in earnings per share of $0.56, compared to $0.79 in the prior year.
The company's operating expenses surged by 38.5% to $133.6 million, driven primarily by a significant increase in research and development costs, which rose to $69.4 million from $34.5 million. This increase was largely due to a $32 million upfront license fee related to in-process research and development (IPR&D) and higher spending on clinical trials for various product candidates. Sales and marketing expenses also saw a modest increase, reflecting ongoing efforts to promote the company's lead product, WAKIX, which is used to treat narcolepsy.
In terms of operational metrics, Harmony reported approximately 8,500 patients on WAKIX as of March 31, 2026, with over 80% of insured lives in the U.S. having formulary access to the product. The company has continued to expand its prescriber base, with around 9,000 healthcare professionals treating patients with narcolepsy. Additionally, Harmony's employee headcount has increased, reflecting its commitment to expanding its research and development capabilities.
Strategically, Harmony has made significant moves to enhance its product pipeline, including the acquisition of Epygenix Therapeutics in April 2024, which provides exclusive rights to clemizole for treating Dravet Syndrome and Lennox-Gastaut Syndrome. The company is also advancing new formulations of pitolisant, with clinical trials for Pitolisant Gastro-Resistant and Pitolisant High-Dose underway. Furthermore, Harmony has entered into various licensing agreements, including a sublicense for an orexin-2 receptor agonist, BP-205, which is in preclinical development for narcolepsy.
Looking ahead, Harmony expects to leverage its existing cash reserves, which totaled $870.5 million as of March 31, 2026, to fund ongoing operations and potential investments. The company anticipates that its current financial position will support its operational liquidity needs for at least the next twelve months. However, it acknowledges the inherent risks associated with product development and market competition, which could impact future performance.
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences is a neuroscience company focused on developing and commercializing treatments for rare neurological disorders. Its core product, WAKIX (pitolisant), addresses narcolepsy and related sleep disorders, offering a non-scheduled, first-in-class therapy with a novel mechanism. The company also advances pipeline candidates for hypersomnia, epilepsy, and neurobehavioral conditions, leveraging scientific innovation and strategic licensing to serve patients with limited treatment options.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.